The Group provides the following notification in accordance with Article 19(3) of the Market Abuse Regulation:
Details of the person discharging managerial responsibilities / person closely associated
Reason for the notification
Person closely associated with Jane Shirley, Joint CEO of Cello Health Insight and CEO of Cello Health Europe
Initial notification /Amendment
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Cello Health plc
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument
Ordinary shares of 10 pence each
Nature of the transaction
Purchase of ordinary shares
Price(s) and volume(s)
- Aggregated volume
Date of the transaction
21 March 2019
Place of the transaction
Cello Health plc
020 7812 8460
Mark Scott, Chief Executive
Mark Bentley, Finance Director
Cenkos Securities plc
0207 397 8900
Notes to Editors
Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.
Cello Health plc enables clients to commercialise and differentiate their assets and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.
Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.
For further information, please visit: https://cellohealthplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
Cello Health PLC's (LON:CLL) Mark Scott tells Proactive London they've seen good growth in profits and strong cash flow for the first half of the year said that he's confident about the rest of the year too.
The group delivered net revenue of £54.5mln for the first six months of the year,...